Reports
Global Gastrointestinal Stromal Tumour Treatment Market: By Treatment Type: Targeted Drug Therapy, Chemotherapy, Radiation Therapy, Surgery; By Indication: Stomach, Small Intestine, Others; By End Use: Hospitals, Cancer Treatment Centres, Clinics, Others; Regional Analysis; Market Dynamics: SWOT Analysis; Competitive Landscape; 2024-2032
Global Gastrointestinal Stromal Tumour Treatment Market Outlook
The global gastrointestinal stromal tumour treatment market is expected to grow at a CAGR of 5.8% in the forecast period of 2024-2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Growing Awareness Regarding the Disease to Aid the Market Growth of Gastrointestinal Stromal Tumour Treatment
The market growth of gastrointestinal stromal tumour treatment is being aided by the growing prevalence of the disease across the globe. The market is propelled by the growing awareness and understanding of this tumour, which has catapulted the market growth tremendously. Further, the ongoing R&D activities across several medical research institutes and organizations worldwide are encouraging the industry growth of gastrointestinal stromal tumour.
Region-wise, North America is a significant market for gastrointestinal stromal tumour treatment and is expected to maintain its significance over the forecast period as well. The healthy market growth in this region could be attributed to the growing adoption of unhealthy dietary options and the consequent bad lifestyles of people, accelerated by the usage of food additives in such food products. Also, the rising prevalence of genetic disorders is a fundamental factor contributing to the speedy growth of this industry in North America in the upcoming years. In addition to this, Europe and the Asia Pacific are expected to observe healthy growth in the forecast period.
Gastrointestinal Stromal Tumour Treatment: Market Segmentation
Gastrointestinal stromal tumours (GISTs) are referred to as soft tissue sarcomas, which can be situated in any part of the digestive system. They are generally found in the stomach and small intestine. GISTs begin to form in specialized nerve cells found in the walls of the digestive system.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
On the basis of treatment type, the market is divided into:
- Targeted Drug Therapy
- Chemotherapy
- Radiation Therapy
- Surgery
- Others
Based on indication, the industry can be segmented into:
- Stomach
- Small Intestine
- Others
By end use, the industry is categorised into:
- Hospitals
- Cancer Treatment Centres
- Clinics
- Others
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Growing Focus on Technological Developments to Aid the Market Growth of Gastrointestinal Stromal Tumour Treatment
The gastrointestinal stromal tumour treatment industry is being driven by the developments in clinical practice guidelines. Further, the robust growth of the healthcare sector and the growing focus on technological developments in this industry is expected to fuel the market growth of gastrointestinal stromal tumour treatment in the forecast period. Furthermore, the growing investments in the medical sector, particularly in emerging economies, are expected to provide lucrative opportunities in the forecast period. All the aforementioned factors are expected to bolster the market growth in the coming years.
Key Industry Players in the Global Gastrointestinal Stromal Tumour Treatment Market
The report gives a detailed analysis of the following key players in the global gastrointestinal stromal tumour treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Pfizer Inc.
- Novartis AG
- Bayer AG
- Blueprint Medicines Corporation
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2018-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Treatment Type, Indication, End Use, Region |
| Breakup by Treatment Type | Targeted Drug Therapy, Chemotherapy, Radiation Therapy, Surgery, Others |
| Breakup by Indication | Stomach, Small Intestine, Others |
| Breakup by End Use | Hospitals, Cancer Treatment Centres, Clinics, Others |
| Breakup by Region | North America, Latin America, Europe, Middle East and Africa, Asia Pacific |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Pfizer Inc., Novartis AG, Bayer AG, Blueprint Medicines Corporation, Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Gastrointestinal Stromal Tumour Treatment Market Analysis
8.1 Key Industry Highlights
8.2 Global Gastrointestinal Stromal Tumour Treatment Historical Market (2018-2023)
8.3 Global Gastrointestinal Stromal Tumour Treatment Market Forecast (2024-2032)
8.4 Global Gastrointestinal Stromal Tumour Treatment Market by Treatment Type
8.4.1 Targeted Drug Therapy
8.4.1.1 Historical Trend (2018-2023)
8.4.1.2 Forecast Trend (2024-2032)
8.4.2 Chemotherapy
8.4.2.1 Historical Trend (2018-2023)
8.4.2.2 Forecast Trend (2024-2032)
8.4.3 Radiation Therapy
8.4.3.1 Historical Trend (2018-2023)
8.4.3.2 Forecast Trend (2024-2032)
8.4.4 Surgery
8.4.4.1 Historical Trend (2018-2023)
8.4.4.2 Forecast Trend (2024-2032)
8.4.5 Others
8.5 Global Gastrointestinal Stromal Tumour Treatment Market by Indication
8.5.1 Stomach
8.5.1.1 Historical Trend (2018-2023)
8.5.1.2 Forecast Trend (2024-2032)
8.5.2 Small Intestine
8.5.2.1 Historical Trend (2018-2023)
8.5.2.2 Forecast Trend (2024-2032)
8.5.3 Others
8.6 Global Gastrointestinal Stromal Tumour Treatment Market by End Use
8.6.1 Hospitals
8.6.1.1 Historical Trend (2018-2023)
8.6.1.2 Forecast Trend (2024-2032)
8.6.2 Cancer Treatment Centres
8.6.2.1 Historical Trend (2018-2023)
8.6.2.2 Forecast Trend (2024-2032)
8.6.3 Clinics
8.6.3.1 Historical Trend (2018-2023)
8.6.3.2 Forecast Trend (2024-2032)
8.6.4 Others
8.7 Global Gastrointestinal Stromal Tumour Treatment Market by Region
8.7.1 North America
8.7.1.1 Historical Trend (2018-2023)
8.7.1.2 Forecast Trend (2024-2032)
8.7.2 Europe
8.7.2.1 Historical Trend (2018-2023)
8.7.2.2 Forecast Trend (2024-2032)
8.7.3 Asia Pacific
8.7.3.1 Historical Trend (2018-2023)
8.7.3.2 Forecast Trend (2024-2032)
8.7.4 Latin America
8.7.4.1 Historical Trend (2018-2023)
8.7.4.2 Forecast Trend (2024-2032)
8.7.5 Middle East and Africa
8.7.5.1 Historical Trend (2018-2023)
8.7.5.2 Forecast Trend (2024-2032)
9 North America Gastrointestinal Stromal Tumour Treatment Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Canada
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
10 Europe Gastrointestinal Stromal Tumour Treatment Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2018-2023)
10.1.2 Forecast Trend (2024-2032)
10.2 Germany
10.2.1 Historical Trend (2018-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 France
10.3.1 Historical Trend (2018-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 Italy
10.4.1 Historical Trend (2018-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Others
11 Asia Pacific Gastrointestinal Stromal Tumour Treatment Market Analysis
11.1 China
11.1.1 Historical Trend (2018-2023)
11.1.3 Forecast Trend (2024-2032)
11.2 Japan
11.2.1 Historical Trend (2018-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 India
11.3.1 Historical Trend (2018-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 ASEAN
11.4.1 Historical Trend (2018-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 Australia
11.5.1 Historical Trend (2018-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Others
12 Latin America Gastrointestinal Stromal Tumour Treatment Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2018-2023)
12.1.2 Forecast Trend (2024-2032)
12.2 Argentina
12.2.1 Historical Trend (2018-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Mexico
12.3.1 Historical Trend (2018-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Others
13 Middle East and Africa Gastrointestinal Stromal Tumour Treatment Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2018-2023)
13.1.2 Forecast Trend (2024-2032)
13.2 United Arab Emirates
13.2.1 Historical Trend (2018-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 Nigeria
13.3.1 Historical Trend (2018-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 South Africa
13.4.1 Historical Trend (2018-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Value Chain Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Company Profiles
16.2.1 Pfizer Inc.
16.2.1.1 Company Overview
16.2.1.2 Product Portfolio
16.2.1.3 Demographic Reach and Achievements
16.2.1.4 Certifications
16.2.2 Novartis AG
16.2.2.1 Company Overview
16.2.2.2 Product Portfolio
16.2.2.3 Demographic Reach and Achievements
16.2.2.4 Certifications
16.2.3 Bayer AG
16.2.3.1 Company Overview
16.2.3.2 Product Portfolio
16.2.3.3 Demographic Reach and Achievements
16.2.3.4 Certifications
16.2.4 Blueprint Medicines Corporation
16.2.4.1 Company Overview
16.2.4.2 Product Portfolio
16.2.4.3 Demographic Reach and Achievements
16.2.4.4 Certifications
16.2.5 Others
17 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Gastrointestinal Stromal Tumour Treatment Market: Key Industry Highlights, 2018 and 2032
2. Global Gastrointestinal Stromal Tumour Treatment Historical Market: Breakup by Treatment Type (USD Billion), 2018-2023
3. Global Gastrointestinal Stromal Tumour Treatment Market Forecast: Breakup by Treatment Type (USD Billion), 2024-2032
4. Global Gastrointestinal Stromal Tumour Treatment Historical Market: Breakup by Indication (USD Billion), 2018-2023
5. Global Gastrointestinal Stromal Tumour Treatment Market Forecast: Breakup by Indication (USD Billion), 2024-2032
6. Global Gastrointestinal Stromal Tumour Treatment Historical Market: Breakup by End Use (USD Billion), 2018-2023
7. Global Gastrointestinal Stromal Tumour Treatment Market Forecast: Breakup by End Use (USD Billion), 2024-2032
8. Global Gastrointestinal Stromal Tumour Treatment Historical Market: Breakup by Region (USD Billion), 2018-2023
9. Global Gastrointestinal Stromal Tumour Treatment Market Forecast: Breakup by Region (USD Billion), 2024-2032
10. North America Gastrointestinal Stromal Tumour Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
11. North America Gastrointestinal Stromal Tumour Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
12. Europe Gastrointestinal Stromal Tumour Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
13. Europe Gastrointestinal Stromal Tumour Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
14. Asia Pacific Gastrointestinal Stromal Tumour Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
15. Asia Pacific Gastrointestinal Stromal Tumour Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
16. Latin America Gastrointestinal Stromal Tumour Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
17. Latin America Gastrointestinal Stromal Tumour Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
18. Middle East and Africa Gastrointestinal Stromal Tumour Treatment Historical Market: Breakup by Country (USD Billion), 2018-2023
19. Middle East and Africa Gastrointestinal Stromal Tumour Treatment Market Forecast: Breakup by Country (USD Billion), 2024-2032
20. Global Gastrointestinal Stromal Tumour Treatment Market Structure
Key Questions Answered in the Report
The global gastrointestinal stromal tumour treatment market is projected to grow at a CAGR of 5.8% between 2024 and 2032.
The major drivers of the industry such as the growing prevalence of the disease, growing awareness and understanding of this tumour, and growing adoption of unhealthy dietary options are expected to aid the market growth.
The key market trend guiding the growth of the industry includes the growing investments in the medical sector, particularly in emerging economies.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The leading treatment types in the market are targeted drug therapy, chemotherapy, radiation therapy, and surgery, among others.
The major indication segments in the industry are stomach and small intestine, among others.
The significant end use sectors in the market are hospitals, cancer treatment centres, and clinics, among others.
The major players in the industry are Pfizer Inc., Novartis AG, Bayer AG, and Blueprint Medicines Corporation, among others.
Analyst Review
The global gastrointestinal stromal tumour treatment market is being driven by the rising prevalence of the disease. Aided by the increasing investments in the medical sector, the market is expected to witness a healthy growth in the forecast period of 2024-2032, growing at a CAGR of 5.8%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. By treatment type, the market is segmented into targeted drug therapy, chemotherapy, radiation therapy, and surgery, among others. On the basis of indication, the industry is divided into stomach and small intestine, among others. Based on end use, the market is segmented into hospitals, cancer treatment centres, and clinics, among others. The major regional markets for gastrointestinal stromal tumour treatment are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa, with North America accounting for the largest share of the market. The key players in the above market include Pfizer Inc., Novartis AG, Bayer AG, and Blueprint Medicines Corporation, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$2799
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER